- Details
- Written by IVN
- Category: Health News
San Rafael, California - BioMarin Pharmaceutical Inc. today announced the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the largest randomized controlled trial evaluating neurocognitive outcomes in patients with phenylketonuria (PKU) treated with the approved therapy Kuvan® (sapropterin dihydrochloride)at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting.
- Details
- Written by IVN
- Category: Health News
Sacramento, California - The USDA has awarded $9 million in grants to develop childhood obesity intervention programs through colleges and universities in 12 states and Puerto Rico. The grants are funded through the Agriculture and Food Research Initiative (AFRI), the flagship competitive grant program authorized under the 2014 Farm Bill.
- Details
- Written by Emil Venere
- Category: Health News
West Lafayette, Indiana - A vibrational spectroscopic imaging technology that can take images of living cells could represent an advanced medical diagnostic tool for the early detection of cancer and other diseases.
- Details
- Written by Shaun Mason
- Category: Health News
Los Angeles, California - Scientists at UCLA’s California NanoSystems Institute and Jonsson Comprehensive Cancer Center have combined their nanotechnology expertise to create a new treatment that may solve some of the problems of using chemotherapy to treat pancreatic cancer.
- Details
- Written by Mark Wheeler
- Category: Health News
Los Angeles, California - After six years of painstaking research, a UCLA-led team has validated the first standardized protocol for measuring one of the earliest signs of Alzheimer’s disease - the atrophy of the part of the brain known as the hippocampus.
- Details
- Written by IVN
- Category: Health News
Washington, DC - Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review. Based on these findings, the study, which is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, may now advance to Phase 3 testing.
Page 298 of 374
